SCHEMBL8097709

SCHEMBL8097709

c1ccc(CN2CCC(Oc3c4c(nc5ccccc35)CCCC4)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
ROCK1 Q13464 2/20 0.47
ROCK2 O75116 1/20 0.47
CCR2 P41597 1/20 0.47
ACHE P22303 6/20 0.46
BCHE P06276 5/20 0.46
ALDH1A1 P00352 3/20 0.46
TSHR P16473 2/20 0.46
HSD17B10 Q99714 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2D6 P10635 2/20 0.46
KCNH2 Q12809 2/20 0.46
KDM4E B2RXH2 1/20 0.46
CACNB4 O00305 1/20 0.46
CACNA1A O00555 1/20 0.46
SLC22A2 O15244 1/20 0.46
SLC22A1 O15245 1/20 0.46
ABCC4 O15439 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8088919 0.84 HRH3 (0.52) KMT2AROCK1ROCK2CCR2ACHE
SCHEMBL11834469 0.75 MEN1 (0.60) EHMT2MEN1KMT2AALDH1A1KDM4E
SCHEMBL5529585 0.74 SCN9A (0.56) KMT2AROCK1ROCK2CCR2ACHE
SCHEMBL14437444 0.73 SCN9A (0.50) KMT2AROCK1ROCK2CCR2ACHE
SCHEMBL11831930 0.73 MEN1 (0.57) MEN1KMT2AACHEALDH1A1KDM4E
SCHEMBL5532963 0.71 NCF1 (0.58) EHMT2ROCK1ROCK2CCR2KCNH2
SCHEMBL8095983 0.71 ROCK1 (0.54) ROCK1ROCK2CCR2ACHEALDH1A1
SCHEMBL5527410 0.70 SMN1; SMN2 (0.50) KMT2AROCK1ROCK2CCR2BCHE
SCHEMBL9463662 0.70 HRH3 (0.56) ROCK1ROCK2CCR2ACHEBCHE
SCHEMBL8103851 0.70 ALOX15 (0.51) ROCK1ROCK2CCR2ACHEBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2009-01-22 US disclosed
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2009-01-22 US disclosed
WO-2009000085-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS TRPV1, TRPV2, TRPA1 EHMT2 4204/4885MEN1 4478/4885KMT2A 3931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.